Intravenous Dexamethasone to support hospitalized COVID-19 patients
QuVa Pharma, Inc. announced confirmation of its ability to provide Dexamethasone Phosphate as a compounded sterile product in a ready-to-administer IV bag, under U.S. Food and Drug Administration (FDA) Drug Shortage guidelines.
QuVa Pharma’s Dexamethasone Phosphate is a compounded sterile product (CSP) available as 6 mg in 25 ml 0.9 percent sodium chloride IV bag and is now available to be ordered.
“Dexamethasone phosphate has been listed on FDA’s Drug Shortages list, as well as their list of compounded drugs for hospitalized COVID-19 patients,” said Stuart Hinchen, Co-founder and Chief Executive Officer at QuVa. “QuVa is committed to supporting hospitals as they advance quality patient care, and a ready-to-administer intravenous presentation will enable hospitals to meet their patient care needs while their pharmaceutical supply chain for this product improves.”
The National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel and the World Health Organization (WHO) updated their recommendations to include systemic corticosteroids, like Dexamethasone 6 mg daily, for hospitalized patients with severe and critical COVID-19. Additionally, following the results of the UK RECOVERY trial3, the European Medicines Agency’s drug evaluation committee, CHMP, has endorsed Dexamethasone use, 6 mg once per day for up to 10 days, for hospitalized COVID-19 patients who require oxygen.
